US Anal Cancer Market

ID: MRFR/MED/18321-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
United States Anal Cancer Market Research Report By Type (Carcinoma In Situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, Basal Cell Carcinoma, Others) By End-user (Hospitals & Clinics, Research & Academic Institutes, Others) By Treatment type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy) - Growth & Industry Forecast 2025 To 2035
US Anal Cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.87%
2024 Market Size$ 217.16 Million
2025 Market Size$ 234.25 Million
2035 Market Size$ 499.6 Million
Key Players
Bristol-Myers Squibb
Merck & Co
Amgen
Eli Lilly and Company
Pfizer
Bayer AG
Opportunities
  • Rising Incidence Rates
  • Emergence of Novel Therapeutics
  • Increased Awareness and Education
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
      1. 4.1.1 Carcinoma In Situ
      2. 4.1.2 Squamous Cell Carcinoma
      3. 4.1.3 Melanoma
      4. 4.1.4 Adenocarcinoma
      5. 4.1.5 Basal Cell Carcinoma
      6. 4.1.6 Others
    2. 4.2 Food, Beverages & Nutrition, BY Treatment type (USD Million)
      1. 4.2.1 Chemotherapy
      2. 4.2.2 Surgery
      3. 4.2.3 Radiation Therapy
      4. 4.2.4 Immunotherapy
    3. 4.3 Food, Beverages & Nutrition, BY End-user (USD Million)
      1. 4.3.1 Hospitals & Clinics
      2. 4.3.2 Research & Academic Institutes
      3. 4.3.3 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck & Co (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Amgen (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eli Lilly and Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bayer AG (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche Holding AG (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Novartis AG (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca PLC (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY END-USER
    5. 6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    8. 6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    11. 6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 (% SHARE)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Anal Cancer Market Segmentation

US Anal Cancer Market By Type (USD Million, 2025-2035)

  • Carcinoma In Situ
  • Squamous Cell Carcinoma
  • Melanoma
  • Adenocarcinoma
  • Basal Cell Carcinoma
  • Others

US Anal Cancer Market By Treatment type (USD Million, 2025-2035)

  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Immunotherapy

US Anal Cancer Market By End-user (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Research & Academic Institutes
  • Others
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.